- News
- Announcements
Announcements
Current & archive
The economic and societal dimension of parental mental illness
Children and adolescents from so-called ‘parents with a mental illness’ have a potentially increased risk of developing negative (health) consequences on the way to their adulthood. One option to mitigate or even prevent negative consequences are family-oriented intervention programmes with social support systems. Gaps in health economic knowledge is a barrier to grasp the overall benefit of these programmes. The report is intended to serve as a source for researchers in order to conduct sound impact assessments of family-oriented intervention programmes and to raise awareness in policy makers about the economic and societal dimensions of mental illness in families.
Publication: HTA Project Report No. 142: https://eprints.aihta.at/1351/
Contact: Christoph Strohmaier
National strategies and programmes for preventing and managing non-communicable diseases in selected countries
Non-communicable diseases (NCDs) are the leading cause of death worldwide and are responsible for a high burden of disease. Many countries have developed national strategies for the management and prevention of NCDs in order to improve the care of chronically ill people or to prevent NCDs. This report aims to provide an overview of national NCD strategies from selected countries and their implementation as well as to summarise evaluation findings on specific programmes. The focus was on chronic respiratory and cardiovascular diseases, diabetes and depression.
Publication: HTA Project Report No. 139: https://eprints.aihta.at/1349/
Contact: Lucia Gassner, Inanna Reinsperger
Process and evaluation of digital health applications in the context of “symptom-checkers”
Digital health applications (DiGAs) are increasingly using diagnostic and therapeutic algorithms. However, for the majority of currently available DiGAs, there is limited evidence on the medical or organizational benefit. Based on a suggested evaluation process for DiGAs outlined by AIHTA (Project report 2020: “Framework for reimbursement decisions of digital health technologies”), the proposed process for an evidence-based evaluation has been further refined and applied in a sample evaluation of a DiGA from the group of the so-called “symptom-checkers”.
Publication: HTA Projekt Report No. 141: https://eprints.aihta.at/1348/
Contact: Reinhard Jeindl
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce our new HSO Fact Sheet.
Fact Sheet No. 71
Sotorasib (Lumykras®): Sotorasib (Lumykras®) as monotherapy for the treatment of advanced NSCLC with KRAS G12C mutation
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce our four new HSO Fact Sheets.
Fact Sheet No. 67
Pembrolizumab (Keytruda) in combination with Lenvatinib (Kisplyx) for the firstline treatment of advanced renal cell carcinoma (RCC)
Fact Sheet No. 68
Pembrolizumab (Keytruda) in combination with Lenvatinib (Kisplyx) for the treatment of advanced or recurrent endometrial carcinoma (EC)
Fact Sheet No. 69
Amivantamab (Rybrevant) as monotherapy for the treatment of patients with advanced non-small cell lung cancer (NSCLC)
Fact Sheet No. 70
Sacituzumab govitecan (Trodelvy) as monotherapy for the treatment of patients with unresectable or metastatic triple-negative breast cancer (mTNBC)
Covid-19: HSS/ Horizon Scanning Living Document (v18 October/November 2021)
The establishment of a HSS/ Horizon Scanning System for Covid19 interventions has the intentions of informing health policy makers at an early stage which interventions (vaccinations and drugs) are currently undergoing clinical trials and to monitor them over the next few months in order to support evidence-based purchasing if necessary. The products are monitored with regard to the status of the clinical studies up to approval and finally evaluated for their benefit and harm.
All work steps are conducted in close international (European) cooperation.
Publications:
- Policy Brief No. 002: http://eprints.aihta.at/1234/
Contact: Claudia Wild
Long COVID care pathways: a systematic review
Due to the expected growing number of long COVID cases and the associated increasing average sick leave durations, it not only places a burden on the patients and their families but also the wider economy, in particular, the workforce. The present systematic review aimed to support preparations and adjustments in the long COVID care planning in Austria by giving (1) an overview of recommendations about long COVID care pathways for adult patients as well as (2) examples of already existing care structures in selected European countries.
Publlication: HTA Project Report No. 135b: https://eprints.aihta.at/1342
Contact: Sarah Wolf
Nivolumab in malignant melanoma: contrasting the evidence from the pivotal trials with the real world evidence (RWE)
Nivolumab is an anti-PD1 checkpoint inhibitor used in patients with advanced malignant melanoma. The aim of this project was to evaluate the real world evidence from observational studies on Nivolumab for the treatment of malignant melanoma and to contrast the results with the evidence from pivotal RCTs. As a result of the comparison, there was good concordance between the outcomes of the included real-world studies and those of the pivotal RCTs across various lines of therapy, with slightly lower response rates.
Publication: HTA Project report No. 140: https://eprints.aihta.at/1341
Contact: Claudia Wild
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce our five new HSO Fact Sheets.
Fact Sheet No. 60
Zanubrutinib (Brukinsa®) as monotherapy for the treatment of patients with waldenström’s macroglobulinaemia (WM)
Fact Sheet No. 62
Ripretinib (Qinlock®) for the treatment of patients with advanced gastrointestinal stromal tumour (GIST)
Fact Sheet No. 64
Pembrolizumab (Keytruda®) in combination with chemotherapy for the treatment of locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC)
Stool DNA testing for colorectal cancer (CRC) screening
Colorectal Carcinoma (CRC) is the third most frequent cancer type, with an incidence and prevalence of approximately 4,800 and 40,000 cases respectively each year in Austria. Multi-target stool DNA (MT-sDNA) testing is a novel non-invasive screening test that may be able to supplement or replace established stool tests by analysing (stool-based) tumour DNA. In this policy brief, the latest available evidence with regard to the clinical benefits and harms of MT-sDNA tests is summarized.
Publication: Policy Brief No. 011: https://eprints.aihta.at/1335
Contact: Gregor Goetz
